Growth Analysis of Asia Pacific Alzheimer’s Disease Therapeutics Market through 2021

Published on : Apr 12, 2016

ALBANY, New York, April 12, 2016: has announced the addition of a report, titled “Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies,” to its expanding database. The report delves into the various facets of the rising prominence of pipeline drugs, therapeutics, and other remedial measures for Alzheimer’s disease (AD) in Asia Pacific due to a rise in the prevalence of the disease over the past few years. The report explains that across the Asia Pacific markets of India, China, Australia, and Japan, the AD market will expand at a CAGR of 7.9% from 2015 to 2021, increasing the market’s valuation from US$3 bn in 2014 to US$5.1 bn by 2021, adds the report.

The report provides answers to some of the pertinent questions related to the APAC AD therapeutics market to understand the growth indicators and development trends that will bridge the supply-demand gap in therapeutics for AD in this region. It provides a detailed snapshot of drug classes that will dominate the Asia Pacific AD therapeutics market till the end of the forecast period. Other than this, approval of novel therapies, clinical outcomes of leading marketed therapies, positioning of new therapies, and clinical outcomes of late-stage drug therapeutics are also discussed in the report. Following this, pipeline drugs for AD that vary from well-established to first-in-class to novel molecules and their molecular targets are looked into in this report.

The report examines at length how business alliances and business conglomerations have been witnessed in the Asia Pacific Alzheimer’s disease market. Since 2006, 170 licensing deals and 104 co-development partnerships have been carried out with respect to AD products. The report further delves into territories of high activity, deal completion trends observed with respect to the development stage of products, and conditions that will assist major licensing or co-development deals to be executed in this region in the future.

The report is an all-important tool to comprehend the current clinical landscape of AD for disease pathogenesis, prognosis, diagnosis, and therapeutics, the data about which is presented by means of textual information and pictorial representations in the report. It assesses the safety and efficacy of treatment options that are currently given for AD, with an emphasis on product profiles of marketed therapies and a heat map representation of a comparison of the safety and efficacy of these drugs.

In this report, pipeline drugs are analyzed and segmented by development stage, molecule type, and molecular target. This is followed by an analysis of the most promising therapies for late-stage Alzheimer’s, which are examined in the purview of clinical outcome, competitiveness, and single-product forecast. Market size growth projections across the four markets in Asia Pacific are provided, which gives insights into medical epidemiology trends, new drug variants, and patent expirations, and their impact on the market’s growth.

About MarketResearchHub

MarketResearchHub is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. marketresearchhub’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top